ReviewOpen biology2017
Progress and prospects of early detection in lung cancer.
Review in Open biology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 455 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
455 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Diagnostic performance of machine learning-based radiomics models for predicting epidermal growth factor receptor mutation status in lung adenocarcinoma in Chinese patients: A systematic review and meta-analysis.The Journal of international medical research · 2026Pooled it
- Efficacy and safety of neoadjuvant immunotherapy plus chemotherapy followed by adjuvant immunotherapy in resectable non-small cell lung cancer: a meta-analysis of phase 3 clinical trials.Frontiers in immunology · 2024Pooled it
- Prognosis of recurrence after complete resection in early-stage lung adenocarcinoma based on molecular alterations: a systematic review and meta-analysis.Scientific reports · 2023Pooled it
- A novel, accurate, and non-invasive liquid biopsy test to measure cellular immune responses as a tool to diagnose early-stage lung cancer: a clinical trials study.Respiratory research · 2023Trial
- Phylogenetic and phylodynamic approaches to understanding the evolution of non-small cell lung cancer using single-cell sequencing.Oncogene · 2026Article
- Early detection of invasive lung cancer and multiorgan metastasis by a collagen-targeted protein MRI contrast agent.Science advances · 2026Article
- Barriers and facilitators to population-based lung cancer screening in Belgium: a qualitative stakeholder analysis in a pre-implementation context.BMC health services research · 2026Article
- Lung cancer detection in CT scans using extracted nodule features and precise multistage segmentation with deep learning based ensemble model.Scientific reports · 2026Article
- Integrative transcriptomic and experimental analysis identifies GREM1 as a pro-metastatic mediator in lung adenocarcinoma.Journal of translational medicine · 2026Article
- Advances in Machine Learning-Assisted Optical Sensing Arrays for Disease Diagnosis.Biomimetics (Basel, Switzerland) · 2026Review
- Quantitative CT analysis in lung cancer research: a bibliometric analysis based on Web of Science [2005-2025].Journal of thoracic disease · 2026Article
- Metal-organic frameworks for breath-based sensors: a review.Mikrochimica acta · 2026Review
- Lung Cancer Screening Access and Cancer Stage at Diagnosis Among American Indian and White Patients.The Journal of rural health : official journal of the American Rural Health Association and the National Rural Health Care Association · 2026Observational
- Healthcare professionals' perspectives on decision-making about lung cancer screening participation: a cross-sectional study in Flanders.BMC medical informatics and decision making · 2026Article
- Sex-Based Disparities in Interval Time to Receipt of Surgical Treatment of Invasive Lung Cancer in Tennessee.Research square · 2026Article
- The Impact of the COVID-19 Pandemic on Diagnosis, Treatment, and Survival of Lung Cancer Patients in Thailand from 2019-2021.Journal of clinical medicine · 2026Article
- Healthcare professionals' perspectives on a population-based lung cancer screening programme in Flanders: a cross-sectional survey study.BMC health services research · 2026Article
- Differences in Lung Cancer Survival by Demographic Characteristics and Social Determinants of Health, United States, 2010-2020.Public health reports (Washington, D.C. : 1974) · 2026Article
- Treatment pathways of lung cancer patients in the Czech Republic: insights from administrative claims data.BMJ open respiratory research · 2026Article
- Performance of multi-planar volume rendering versus maximum intensity projection and minimum intensity projection on pulmonary nodule detection.Quantitative imaging in medicine and surgery · 2026Article
395 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Lung cancer is the leading cause of cancer-related death in the world. It is broadly divided into small cell (SCLC, approx. 15% cases) and non-small cell lung cancer (NSCLC, approx. 85% cases). The main histological subtypes of NSCLC are adenocarcinoma and squamous cell carcinoma, with the presence of specific DNA mutations allowing further molecular stratification. If identified at an early stage, surgical resection of NSCLC offers a favourable prognosis, with published case series reporting 5-year survival rates of up to 70% for small, localized tumours (stage I). However, most patients (approx. 75%) have advanced disease at the time of diagnosis (stage III/IV) and despite significant developments in the oncological management of late stage lung cancer over recent years, survival remains poor. In 2014, the UK Office for National Statistics reported that patients diagnosed with distant metastatic disease (stage IV) had a 1-year survival rate of just 15-19% compared with 81-85% for stage I.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.